The brave new world of medicine by testimonial

Cassels, Alan
April 2011
CMAJ: Canadian Medical Association Journal;4/5/2011, Vol. 183 Issue 6, p728
Academic Journal
The article offers the author's insights on patient testimonials on drug policy decision-making. He mentions a website launched by the British Columbia Ministry of Health inviting patient input into the decision-making process at its Drug Benefit Council. He questions the U.S. Food and Drug Administration (FDA) drug review process on the approval of the drug Benlysta for lupus treatment. He believes that testimonials do not provide sufficient clinical evidence on creating drug policy decisions.


Related Articles

  • FDA Leaders Stress Science and Compliance. Wechsler, Jill // BioPharm International;Oct2009, Vol. 22 Issue 10, p16 

    The article discusses the new rules and policies announced by the newly appointed U.S. Food and Drug Administration (FDA) Commissioner Margaret Hamburg. It states that Hamburg intends to position the FDA as a science-based agency where politics do not override medical judgment and enforce...

  • Lupus drug reviewed. Morrison, Chris // Nature Biotechnology;Jun2001, Vol. 19 Issue 6, p500 

    Focuses on the decision of the U.S. Food & Drug Administration's Arthritis Advisory Committee on the fate of Aslera Genelabs Technologies' synthetic dehydroepiandrosterone treatment for systematic lupus erythematosus. Composition of the committee; Criticism of the treatment.

  • Breakthrough Approval for Lupus Drug.  // Chain Drug Review;3/28/2011, Vol. 33 Issue 6, p65 

    The article reports on the approval made by the Food and Drug Administration to the new drug Benlysta for lupus treatment in the U.S.

  • Research & Markets: FDA Ends the 50-Year Long Wait for Lupus Patients - Benlysta Set to Become the Next Blockbuster.  // Biomedical Market Newsletter;5/7/2011, p561 

    The article offers information on a report entitled "FDA Ends the 50-Year Long Wait for Lupus Patients: Benlysta Set to Become the Next Blockbuster" from GlobalData which provides key update on the landmark approval of the first lupus drug to be approved by the U.S. Food & Drug Administration in...

  • Health Economic Analysis. Schultz, Monica; Lyle, Chris // Applied Clinical Trials;May2009, Vol. 18 Issue 5, p40 

    The article discusses the cost effectiveness criteria in the U.S. It highlights the cost effectiveness criteria that created controversy which remained in circulation for 10 years. It notes the argument on incorporating costs and outcome considerations for treatment decision of a patient that...

  • Industry News.  // MLO: Medical Laboratory Observer;Sep2014, Vol. 46 Issue 9, p7 

    The article discusses developments in the healthcare industry, particularly in the U.S., as of September 2014. It cites the move by the U.S. Food and Drug Administration (FDA) to take steps in ensuring the reliability of certain diagnostic tests. It reports the definitive agreement signed by...

  • Development of an FDA guidance document for clinical trials in SLE. Siegel, J N // Lupus;1999, Vol. 8 Issue 8, p581 

    To make the process of developing new therapeutic agents more efficient, it is critical that investigators and industry sponsors understand in advance what information they will need to provide to the US Food and Drug Administration (FDA) in order to license and market their product. To...

  • Methodologic Issues in the Validation of Putative Biomarkers and Surrogate Endpoints in Treatment Evaluation for Systemic Lupus Erythematosus. Liang, Matthew H.; Simard, Julia F.; Costenbader, Karen; Dore, Benjamin T.; Ward, Michael; Fortin, Paul R.; Illei, Gabor G.; Manzi, Susan; Mittleman, Barbara; Buyon, Jill; Gupta, Samardeep; Abrahamowicz, Michal // Endocrine, Metabolic & Immune Disorders - Drug Targets;Mar2009, Vol. 9 Issue 1, p108 

    No new drugs have been approved for the treatment of systemic lupus erythematosus (SLE) by the Food and Drug Administration for the last 30 years. One barrier has been the lack of validated biomarkers and surrogate endpoints. Validation of SLE biomarkers in the past have been methodologically...

  • FDA Panel Backs HGSI's Benlysta for Lupus. Young, Donna // BioWorld Today;11/17/2010, Vol. 21 Issue 223, p1 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) panel of Benlysta from Human Genome Sciences Inc. as a treatment for adults with systemic lupus erythematosus (SLE). In a 13-2 vote, Benlysta has become the first new lupus treatment in more than 50 years to enter...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics